Ultrasound catheter system

Information

  • Patent Grant
  • 11344750
  • Patent Number
    11,344,750
  • Date Filed
    Friday, January 25, 2019
    5 years ago
  • Date Issued
    Tuesday, May 31, 2022
    2 years ago
Abstract
A method of recanalizing a lumen of a vessel includes positioning an ultrasonic device having a distal end in a first position within the lumen of the vessel; transmitting pulsed ultrasonic vibrations though the ultrasonic device to the distal end; and advancing the distal end through the lumen to recanalize the vessel.
Description
BACKGROUND
Field of the Invention

This disclosure generally relates to a device, system, and method for generating and transmitting ultrasonic vibrations to a treatment location. More particularly, the disclosure relates to an ultrasound device, system, and method for ablating obstructions within tubular anatomical structures such as blood vessels.


Description of the Related Art

There are many procedures and systems for treating vascular or venous obstructions that are occluded with atheroma, plaque, calcific material, and the like. Such obstructions are often referred to as vascular occlusions. Occlusions can be treated, for example, by a surgical bypass procedure or a catheter-based intervention such as angioplasty.


Ultrasound systems and devices have been proposed for use in ablating or removing obstructive material from blood vessels. Ultrasound catheters have been utilized to ablate various types of obstructions from blood vessels of humans and animals Successful applications of ultrasound energy to smaller blood vessels, such as the coronary arteries, require the use of relatively small diameter ultrasound catheters which are sufficiently small and flexible to undergo transluminal advancement through the tortuous vasculature of the aortic arch and coronary tree. These ultrasound catheters incorporate a very small diameter ultrasound transmission member which extends through such catheters.


SUMMARY OF THE INVENTION

In some embodiments, a therapeutic ultrasonic vibration delivery system comprises an elongate ultrasound transmission device having a distal end and a proximal end and an ultrasonic driver coupled to the proximal end of the transmission device and configured to drive the transmission device such that the distal end of the transmission device vibrates at a frequency of at least 18 kHz. In some aspects, the transmission device comprises an ultrasound transmission member disposed within a lumen of a catheter body. The ultrasonic driver may include a signal generator coupled to an ultrasound transducer. The ultrasonic driver may be configured to deliver pulses of ultrasonic vibration. The ultrasonic driver may be configured to drive the transmission device at a resonant frequency of the transmission device.


In some embodiments, a method of recanalizing a lumen of a vessel comprises positioning an ultrasonic device having a distal end in a first position within the lumen of the occluded vessel, transmitting an ultrasonic vibration of at least 18 kHz though the ultrasonic device, and advancing the distal end through the occluded vessel to recanalize the vessel. The positioning step may include snaking the device through a tortuous path. In some aspects, the transmitted vibration is about 40 kHz.


In some embodiments, a therapeutic ultrasonic vibration delivery system comprises an elongate ultrasound transmission device having a distal end and a proximal end, and an ultrasonic driver coupled to the proximal end of the transmission device and configured to drive the transmission device in a pulsed mode. The pulsed mode may drive the device with a duty cycle of about 50% which may be optimized for ablating a particular substrate.


In some embodiments, a method of recanalizing a lumen of a vessel comprises positioning an ultrasonic device having a distal end in a first position within the lumen of the vessel, transmitting pulsed ultrasonic vibrations though the ultrasonic device to the distal end, and advancing the distal end through the vessel to recanalize the vessel. The pulsed ultrasonic vibrations can increase the displacement of the distal end of the ultrasonic device.


In some embodiments, a therapeutic ultrasonic vibration delivery system comprises an elongate ultrasound transmission device having a distal end and a proximal end and an ultrasonic driver coupled to the proximal end of the transmission device and configured to drive the transmission device through a range of ultrasonic frequencies. The ultrasonic driver may be configured to drive the transmission device by sweeping continuously through a range of ultrasonic frequencies. The range of ultrasonic frequencies may be between about 18 kHz and 22 kHz and may include at least one resonant frequency of the transmission device.


In some embodiments, a method of recanalizing a lumen of a vessel comprises positioning an ultrasonic device having a distal end in a first position within the lumen of the vessel, transmitting a range of ultrasonic vibrations though the ultrasonic device to the distal end, and advancing the distal end through the lumen of the vessel to recanalize the vessel.


In some embodiments, a therapeutic ultrasonic vibration delivery system comprises an elongate ultrasound transmission device having a distal end and a proximal end, a detector configured to determine a resonant frequency of the ultrasound transmission device, and an ultrasonic driver coupled to the proximal end of the transmission device and configured to drive the ultrasound transmission device at the resonant frequency. The resonant frequency may be determined by using a measurement pulse transmitted through the transmission device.


In some embodiments, a therapeutic ultrasonic vibration delivery system comprises an elongate ultrasound transmission device having a distal end and a proximal end, an ultrasonic driver coupled to the proximal end of the transmission device and configured to transmit ultrasonic vibrations through the transmission device, and a detector coupled to the transmission device and configured to determine the displacement of the distal end of the transmission device. The detector may be configured to determine the displacement of the distal end of the transmission device at least in part by detecting a reflected vibration.


In some embodiments, a method of controlling the frequency of vibration applied to an ultrasound device, comprises applying a vibration having an ultrasonic frequency to the ultrasound device, detecting a reflected vibration, and applying a second vibration based at least in part on the detected vibration.


In some embodiments, a method of recanalizing a lumen of a vessel, comprises positioning an ultrasonic device having a distal end in a first position within the lumen of the vessel, determining a resonant frequency of an ultrasound transmission device, vibrating the ultrasound transmission device at the resonant frequency, and advancing the distal end through the occluded vessel to recanalize the vessel. The determining step may occur when the distal end is within the lumen of the occluded vessel.


In some embodiments, a therapeutic ultrasonic vibration delivery system comprises an elongate ultrasound transmission device having a distal end and a proximal end, and an ultrasonic driver coupled to the proximal end of the transmission device and configured to drive the transmission device such that the distal end of the transmission device vibrates at a frequency of at least 20 kHz. The ultrasonic driver may be configured to deliver pulses of ultrasonic vibrations. The pulsed delivery may include a pulse repetition frequency between about 5 milliseconds and 30 milliseconds. In some embodiments, the pulsed delivery comprises delivering a first vibration for a first time period and delivering a second vibration for a second time period. In some embodiments, the pulsed delivery comprises applying a first vibration for a first time period, and then turning the driver off for a second time period, followed by applying a third vibration for a third time period. In some embodiments, a method of driving a therapeutic ultrasound device comprises determining a resonant frequency of an ultrasound transmission device and vibrating the ultrasound transmission device at the resonant frequency.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is a perspective view of an ultrasound system according to a preferred embodiment of the present invention.



FIG. 2A is a side view of the ultrasound device shown in FIG. 1.



FIG. 2B is a cross-sectional side view of the ultrasound device shown in FIG. 2A.



FIG. 3 is a schematical side view of the ultrasound device in one mode of operation.



FIGS. 4-6 are flow diagrams illustrating methods of recanalizing vessels according to some embodiments.





DETAILED DESCRIPTION OF CERTAIN PREFERRED EMBODIMENTS

The following description and the accompanying figures describe and show the preferred embodiments as well as demonstrate several possible configurations for a device, system, and method. The illustrations are not intended to limit the disclosed aspects and features of the invention to the specified embodiments or to usage only with the illustrated device. Those of skill in the art will recognize that the disclosed aspects and features of the invention are not limited to any particular embodiment of a device, which may include one or more of the inventive aspects and features described herein.


To assist in the description of these components of the device, the following coordinate terms are used. A “longitudinal axis” is generally parallel to a portion of the device as well as parallel to the axis of a vessel through which the device can travel. A “lateral axis” is normal to the longitudinal axis. A “transverse axis” extends normal to both the longitudinal and lateral axes. In addition, as used herein, “the longitudinal direction” refers to a direction substantially parallel to the longitudinal axis; “the lateral direction” refers to a direction substantially parallel to the lateral axis; and “the transverse direction” refers to a direction substantially parallel to the transverse axis. The term “axial” as used herein refers to the axis of the device, and therefore is substantially synonymous with the term “longitudinal” as used herein. Also, the terms “proximal” and “distal,” which are used to describe the present system, are used consistently with the description of the exemplary applications (i.e., the illustrative examples of the use applications). Thus, proximal and distal are also used in reference to the respective ends of the device.


To facilitate a complete understanding of the embodiments, the remainder of the detailed description describes the system with reference to the Figures; wherein like elements among the embodiments are referenced with like numerals throughout the following description.



FIG. 1 shows an example of a perspective view of an ultrasound system 100 that can be used to ablate vascular occlusions. The ultrasound system 100 includes an ultrasound device 120 which is releasably coupled to an ultrasound transducer 126. The ultrasound transducer 126 is electrically coupled to a signal generator 127.


The ultrasound device 120 may include an elongate body having a proximal portion 122 and a distal portion 121. The ultrasound device 120 may be an ultrasonic energy delivery member, or a catheter having at least one lumen extending longitudinally with an ultrasound transmission member extending therethrough.


The ultrasound device 120 may also include a Y-connector 123 that is operatively coupled to the ultrasound transducer 126. For example, the Y-connector 123 may be coupled to the ultrasound transducer 126 by way of a device knob 124 and a slide collar 125. The ultrasound transducer 126 may be connected to a signal generator 127, which may be coupled to a foot actuated on-off switch 128. The signal generator 127 can be supported by an IV pole 129. When the on-off switch 128 is depressed, the signal generator 127 can send an electrical signal to the ultrasound transducer 126, which converts the electrical signal to ultrasound energy. Such ultrasound energy can subsequently pass through the ultrasound device 120 and be delivered to the distal portion 121. A conventional guidewire may be utilized in conjunction with the device 120. The distal portion 121 may comprise a distal end 300.


The frontal portion of the Y-connector 123 may be connected to the proximal end 122 of the ultrasound device 120 using techniques that are well-known in the art. An injection pump 130 or IV bag or syringe may be connected, by way of an infusion tube 131, to an infusion port or sidearm 132 of the Y-connector 123. The injection pump 130 can be used to infuse coolant fluid into and/or through the device 120. Such flow of coolant fluid may be utilized to prevent overheating of the ultrasound transmission member and may serve to bathe the outer surface of the ultrasound transmission member, thereby providing for an equilibration of temperature between the coolant fluid and the ultrasound transmission member. The temperature and/or flow rate of coolant fluid may be adjusted to provide adequate cooling and/or other temperature control of the ultrasound transmission member. The irrigation fluid can include a pharmacological agent and/or microbubbles. In addition to the foregoing, the injection pump 130 or syringe may be utilized to infuse a radiographic contrast medium into the device 120 for purposes of imaging. Examples of iodinated radiographic contrast media which may be selectively infused into the ultrasonic device 120 via the injection pump 130 are commercially available as Angiovist 370 from Berlex Labs, Wayne, N.J. and Hexabrix from Malinkrodt, St. Louis, Mo.


Generally, the ultrasonic device 120 may include any suitable number of side-arms or ports for passage of a guidewire, application of suction, infusing and/or withdrawing irrigation fluid, dye and/or the like, or any other suitable ports or connections. Also, the device may be used with any suitable ultrasound transducer 126, signal generator 127, coupling device(s) and/or the like. Therefore, the exemplary embodiment shown in FIG. 1 and any following descriptions of proximal apparatus or systems for use with ultrasound devices 120 should not be interpreted to limit the scope of the present invention as defined in the appended claims.



FIG. 2A is a side view of the ultrasound device 120 shown in FIG. 1. As illustrated, the distal portion of the Y-connector 123 is coupled to a catheter body 204. The ultrasound transmission member 230 can pass through the device knob 124, Y-connector 123, and catheter body 204, and abut at least a portion of the distal head of the catheter body 204. In some embodiments, the ultrasound transmission member 230 can emerge through the distal end of the catheter body 204 rather than abut at the distal end of the catheter body 204. In some embodiments, the distal tip of the ultrasound transmission member 230 is secured directly to the distal end of the catheter body 204.


Continuing with FIG. 2A, the device knob 124 includes a proximal housing 208. The housing 208 may include one or more surface features 212 for increasing the outer surface area of housing 208. Increased surface area can enhance the ability of housing 208 to dissipate heat generated by ultrasound transmission member 230. Surface features 212 may be of any suitable size or shape and can include, for example, ridges, jags, undulations, grooves or the like. Any suitable number of surface features 212 may be used. Additionally, the housing 208 may be made of one or more heat dissipating materials, such as aluminum, stainless steel, any other conductive metal(s), or any suitable non-metallic conductive material.


The catheter body 204 may be a generally flexible, tubular, elongate member, having any suitable diameter and length for reaching a vascular occlusion. In some embodiments, for example, the catheter body 204 has a length in the range of about 100-200 cm. In one embodiment, the catheter body 204 has an outer diameter in the range of about 0.5-5.0 mm. In other embodiments, for use in relatively small vessels for example, the catheter body 204 may have an outer diameter in the range of about 0.25-2.5 mm. However, any other suitable length or diameter may be used without departing from the scope of the present invention. Examples of catheter bodies similar to those which may be used in the present invention are described in U.S. Pat. Nos. 5,267,954 and 5,989,208, which are herein incorporated by reference in their entireties. In one embodiment, the catheter body 204 is formed of a flexible polymeric material such as nylon (Pebax™) manufactured by Atochimie, Cour be Voie, Hauts Ve-Sine, France. The catheter body 204 can insulate the ultrasound transmission member 230 and prevent an operator's hands from contacting the ultrasound transmission member 230 during use of the device.


In some embodiments, the catheter body 204 includes one or more radiopaque markers located at a distal portion 214 of the catheter body 204. In one embodiment, the distal portion 214 is made of a radiopaque polymer or similar materials known in the art. The radiopaque materials can increase visibility under fluoroscopy and facilitate the correct positioning of the device. In another embodiment, intravascular ultrasound or other imaging modalities may be employed. Alternate imaging techniques may include Optical Coherence Tomography (OCT) and/or magnetic fields (Stereotaxis Inc.) to further facilitate positioning of the distal portion 214 within a patient.



FIG. 2B shows a cross-sectional view of the ultrasound device 120 shown in FIG. 2A. As depicted, the housing 208 can include an inner cavity 244. Disposed within the cavity 244 is a sonic connector 252. The ultrasound transmission member 230 extends in a distal direction from the sonic connector 252 and through the cavity 244.


The inner cavity 244 may include one or more vibration absorption members 250. The vibration absorption members 250 can increase the ease of use by decreasing vibrations transmitted from the ultrasound transmission member 230 through the housing 208. The sonic connector 252 can facilitate the coupling of the ultrasound transmission member 230 to an ultrasound transducer device 126. The ultrasound transmission member 230 may extend distally from the sonic connector 252, through the inner cavity 244, Y-connector 123, and catheter body 204.


Continuing with FIG. 2B, the sidearm 132 may include a lumen 232 in fluid communication with a lumen 223 in the Y-connector 123. The lumen 223 in the Y-connector 123 can be in fluid communication with a lumen extending through the catheter body 204. Thus, fluid introduced into the sidearm 132 may flow into and through the catheter body 204 and contact the ultrasound transmission member 230. The fluid may flow out of the catheter body 204 through apertures in the distal portions or through any other suitable apertures or openings, such as apertures located in the catheter body 204 itself.


Any suitable fluid may be passed through the sidearm 132 and catheter body 204. Suitable fluids include, for example, refrigerated fluids, lubricious fluids, saline, saturated saline, super-saturated saline, contrast/saline mixtures, or the like. Cooling and/or lubricating the ultrasound transmission member 230 may reduce friction and/or wear and tear of the ultrasound transmission member 230, thus prolonging the ultrasound transmission member's useful life and enhancing overall performance.


As shown in FIG. 2B, the catheter body 204 defines a main lumen. However, the catheter body 204 can comprise an elongate tube with one or more lumens extending longitudinally therethrough. With continued reference to FIG. 2A, extending longitudinally through the main lumen of the catheter body 204 is an elongate ultrasound transmission member 230 having a proximal end. The proximal end may be removably connectable to an ultrasound transducer via the sonic connector 252 such that ultrasound energy can pass through the ultrasound transmission member 230 from the proximal end to the distal portion of the ultrasound transmission member 230.


In some embodiments, the ultrasound transmission member 230, wire, or wave guide extends longitudinally through a lumen of the catheter body 204. Ultrasonic energy can travel through the ultrasound transmission member 230 from an ultrasound transducer 126 connected to the proximal end of housing 208 to the distal portion of the device. The ultrasound transmission member 230 may operate at frequencies between about 18 kHz to about 150 kHz. In one embodiment, the frequency of vibration is about 20 kHz. In some embodiments, the ultrasound transmission member 230 operates at frequencies between about 40 kHz to about 150 kHz. In one embodiment, the frequency of vibration is greater than about 40 kHz. The ultrasound transmission member 230 may operate in continuous mode, pulse mode, or combination of both.


The ultrasound transmission member 230 may be formed of any material capable of effectively transmitting ultrasonic energy from the ultrasound transducer to the distal end of the ultrasound transmission member 230. These materials include, but are not limited to, metals such as pure titanium or aluminum, or titanium or aluminum alloys, such as NiTi. The ultrasound transmission member 230 may include one or more tapered regions and/or steps. The tapered regions and steps may increase and/or decrease in width or diameter along the length of the ultrasound transmission member 230 in the distal direction. In one embodiment, the ultrasound transmission member 230 includes at least one portion tapered in a direction extending distally from the proximal end. In another embodiment, the ultrasound transmission member 230 is continuously tapered in a direction extending distally from the proximal end. In one embodiment, the ultrasound transmission member 230 tapers in diameter from about 800 μm proximally, to about 200 μm distally.


Additional details of ultrasound systems and devices that include ultrasound transmission members (and their distal tips), catheter bodies (and their distal tips), ultrasound transducers, sonic connectors, and their connections to ultrasound devices are disclosed, for example, in U.S. Pat. Nos. 5,827,203, 6,007,514, 6,427,118; 6,702,748; 6,855,123; 6,942,620; 6,942,677; 7,137,963; 7,220,233; 7,297,131; 7,335,180; 7,393,338; 7,540,852, 7,604,608, 8,133,236 and in U.S. Pat. App. Pub. Nos. 2006/0161098, 2007/0239027, 2008/0108937, 2008/0287804, 2010/0317973, the disclosures of which are hereby incorporated by reference in their entireties.


Returning to FIG. 1, the signal generator 127 can send electrical signals to the ultrasound transducer 126. The ultrasound transducer 126 can then convert the electrical signals to ultrasonic vibrations. The ultrasonic vibrations can then be transmitted through the ultrasound transmission member and delivered to a treatment location. A treatment location can be an area of a vessel and/or vessel wall that has stenosis or restenosis. Vessels can include veins and arteries. The methods and devices described herein can also be applied to other body lumens and organs, for example, biliary ducts.


In use, the system must provide sufficient ultrasonic vibration to the treatment location in order to provide a therapeutic benefit. For example, when used to open or recanalize a fully or partially blocked vessel or lumen, the system 100 must provide enough vibration to penetrate and/or ablate the blockage. Often, after treating an occluded vessel, a stent can be placed in the vessel to enlarge and/or support the vessel. Various system parameters can be adjusted and optimized as will be explained below.


In some embodiments, the power delivery can be optimized to deliver ultrasonic vibrations to a treatment site at the end of a tortuous path. For example, the signal generator 127, ultrasound transducer 126, and/or any other suitable component can be configured such that the ultrasound device 120 can penetrate and/or ablate occlusions when the ultrasound device 120 is threaded through tortuous paths. That is to say, when the ultrasound device 120 is threaded through the vasculature to a treatment location, the ultrasound device 120 must bend. The more tortuous the path through the vasculature (for instance, during coronary applications), the more bends the ultrasound device 120 must undertake. Higher frequency (shorter wavelength) ultrasonic energy travels easier around bends than lower frequency (longer wavelength) ultrasonic energy. Because higher frequency ultrasonic energy (for example 40 kHz) travels easier around bends than lower frequency ultrasonic energy, less energy is lost when traveling through the ultrasonic device and more energy is delivered to the treatment location. Accordingly, the system disclosed herein can include a signal generator 127 and/or ultrasound transducer 126 configured to drive the ultrasound device 120 at frequencies greater than or equal to about 18 kHz. In some embodiments, the signal generator 127 is configured to provide drive frequencies from about 18 kHz to about 150 kHz. In some embodiments, the ultrasound transducer 126 is configured to deliver ultrasonic vibrations from about 18 kHz to about 150 kHz through the ultrasonic device. In some embodiments, mass of the ultrasound transducer 126 is reduced in order to run at higher drive frequencies, for example, above 40 kHz.


In some embodiments, power delivery is optimized by delivering pulsed ultrasonic vibrations to a treatment location. With reference to FIG. 1, in some embodiments, the signal generator 127, ultrasound transducer 126, and/or any other suitable component includes one or more actuators 119 for switching between two or more modes or types of ultrasound energy transmission through the ultrasonic device 120. Actuator 119 may be used, for example, to switch between the transmission of pulsed ultrasound signal and a continuous ultrasound signal. Providing two or more different types of ultrasound signal may enhance disruption of a vascular occlusion, and in various embodiments, switching between types of signals may be performed in any order desired, as many times as desired, without stopping the transmission of ultrasound energy to make the switch and/or the like. Although actuator 119 is illustrated on the signal generator 127 in FIG. 1, it may be given any other location and configuration. Some embodiments do not include an actuator; rather the signal generator 127 and/or the ultrasound transducer 126 are configured to operate in only a pulsed mode or in only a continuous mode or configured to operate in a self-switching mode based at least in part upon the distal environment and/or the reflected energy.


In a pulsed operation, parameters such as the number of pulses occurring in a given time period (pulse frequency), the time from the beginning of one pulse to the beginning of the next (pulse period), and the time it takes for one pulse to occur (pulse duration) can all be adjusted and selected. For example, in certain embodiments the time between pulses is 5 milliseconds which results in much faster “drilling.” The signal generator 127 can further be operated at a higher frequency, such as 135 kHz.


In some embodiments, the signal generator 127, ultrasound transducer 126, and/or any other suitable component may be configured to provide a pulsed ultrasound signal. The pulsed ultrasound signal can have any suitable duty cycle. In some embodiments, the duty cycle can be in the range of approximately 30-70% (i.e., off 70-30%) or any other suitable range. The frequency of the duty cycle can be any suitable frequency and can be adjusted prior to use or during use. In other words, the length of time that the device is on or off in a given period can be manipulated and optimized. For example, the duty cycle can be optimized for particular materials that the device may encounter. In particular, the device can penetrate harder materials in pulsed operation. Thus, the applied wave form can be altered and/or optimized.


In some embodiments, when ultrasound energy travels through the ultrasound device, there is an initial period of time during which the distal tip of the ultrasound device vibrates in a more random and aggressive manner than during later time periods in the same activation cycle in part because the tip vibrations settle into a steady state. These initial vibrations may provide the greatest erosion performance against harder substrates. Therefore, by pulsing the energy on and off rapidly, this start-up energy can be supplied many more times in a given time period. For example, in some embodiments, a 50% duty cycle with 30 ms on and 30 ms off pulses can provide one start-up burst every 60 ms. A 50% duty cycle with 10 ms on and 10 ms off can provide three start-up bursts every 60 ms. Furthermore, a 33% duty cycle with 10 ms on and 20 ms off can provide two start-up bursts every 60 ms. In some embodiments, the ultrasound device can operate at lower temperature and fatigue after a longer time period, at least in part because of the reduced duty cycle.


The signal generator 127 can be configured to provide square wave signals or sinusoidal wave signals to the ultrasound transducer 126. In some embodiments, the signal generator 127 is configured to provide any programed wave shape. In one embodiment for example, the signal generator 127 is configured to provide one or more input signals to the ultrasound transducer 126 separated by time gaps when no signal is provided. The pulse period, pulse frequency, and pulse duration can be selected and optimized.


The pulsed operation of the devices disclosed herein can increase displacement of the distal tip 300 and can cause the distal tip 300 to move erratically. This increased displacement and erratic movement enhances the ability of the distal tip 300 to penetrate hard and/or dense materials. In other words, operating the device in a pulsed ultrasonic mode can increase the effectiveness of the device by increasing movement of the distal end of the ultrasonic device to, for example, ablate the desired material.



FIG. 4 is a flow diagram illustrating a method 400 of recanalizing a vessel using of pulsed ultrasonic vibrations. The method can begin at block 401 by positioning an ultrasonic device having a distal end in a first position within the lumen of a vessel. The first position may be proximal to an occlusion. The occlusion may be a partial or total occlusion. The ultrasonic device may include one or more or the components described above. The method 400 can continue at block 405 by transmitting pulsed ultrasonic vibrations to the distal end of the ultrasonic device. The pulsed ultrasonic vibrations can increase the displacement of the distal tip and improve performance of the ultrasonic device by ablating the occlusion faster and to a greater extent than previous devices. In some embodiments, the pulsed vibrations include transmitting a first frequency for a first time period, followed by transmitting a second frequency for a second time period. In some embodiments, the vibrations are applied for a first time period followed by a second time period when no vibrations are applied followed by a third time period where vibrations are again applied. The vibrating distal end of the device may be advancing through the occlusion while ultrasonic vibrations are applied to the proximal end of the device. The method 400 can end at block 409 by advancing the distal end to through the vessel to recanalize the vessel.


With reference to FIG. 1, in some embodiments power delivery is optimized by configuring the ultrasound system 100 to operate at the resonant frequency of the ultrasound device 120 for at least a period of time during use. In general, when the ultrasonic frequency applied to the ultrasound device 120 matches the natural frequency of the ultrasound device 120 it will begin to resonate. The effectiveness of the ultrasound device 120 is enhanced at resonance because the amplitude with which the distal end 300 of the ultrasound device moves 120 is maximized at resonance. As such, the distal end 300 can penetrate material and/tissue more effectively during resonant vibration because the distal end 300 moves hack and forth across the greatest distance and more energy is imparted against the blockage.


In some embodiments, the signal generator 127, ultrasound transducer 126, and/or any other suitable component can be configured to operate at the resonant frequency of a particular ultrasound device 120 during use. For example, a particular ultrasound device 120 has a particular resonant frequency associated with the device 120. The resonant frequency can depend on the unique characteristics of the ultrasound device 120 (for example, the particular ultrasound transmission member and/or catheter body used and/or the particular configuration of the distal end). Factors such as length, thickness, and material of the ultrasound transmission member and/or catheter body can also affect the resonant frequency. Thus, prior to use, the resonant frequency for a particular ultrasound device 120 can be determined. In general, the resonant frequency can be expected to be similar for the particular ultrasound device 120 within manufacturing tolerances. However, in some embodiments, the resonant frequency of each particular ultrasound device can be determined prior to use.


Furthermore, during use, the resonant frequency of the particular ultrasound device 120 changes because of factors such as the amount of tortuosity the ultrasound device 120 and/or components thereof is subjected to, the temperature, and the load on the distal end 300. These changing factors during use of the ultrasound device 120 can change the resonant frequency of the device by, for example, about +/−10%.


In some embodiments, the ultrasound system 100 is configured such that the ultrasound device 120 operates at resonant frequency for at least a period of time by continually sweeping across a range of applied ultrasonic frequencies during operation. For example, the signal generator 127, ultrasound transducer 126, and/or any other suitable component can be configured to apply ultrasound vibration to the ultrasound device 120 in a back and forth sweeping manner through a range of frequencies. By sweeping across a given range of frequencies, the ultrasound device 120 is likely to achieve resonance for at least a portion of time during the sweep.



FIG. 5 is a flow diagram illustrating a method 500 of recanalizing a vessel by applying a range of ultrasonic vibrations to an ultrasound transmission device. The method can begin at block 501 by positioning the ultrasonic device having a distal end in a first position within the lumen of a vessel. The first position may be proximal to a partial or total occlusion. The distal end of the ultrasonic device may contact the occlusion. The ultrasonic device may include one or more or the components described above. The method 500 can continue at block 505 by transmitting a range of ultrasonic vibrations to the distal end of the ultrasonic device. The range of ultrasonic vibrations may be between 1 kHz and 10 MHz. In some embodiments, the range is between 18 kHz and 22 kHz and/or includes at least one resonant frequency of the transmission device. By delivering a range of ultrasonic vibrations the displacement of the distal tip may be increased, improving performance of the ultrasonic device by ablating the occlusion faster and to a greater extent than previous devices. The method 500 can end at block 509 by advancing the distal end through the vessel to recanalize the vessel.


In some embodiments, prior to using the device, the resonant frequency for a particular ultrasound device 120 design can be determined. The system 100 can then be configured to sweep across this resonant frequency in a range of about +/−10% of the known resonant frequency. In one embodiment, for example, the vibration applied to the ultrasound device 120 sweeps continually back and forth between the range of 18 kHz and 22 kHz. In another embodiment, the vibration applied to the ultrasound device 120 sweeps continually from 18 kHz to 22 kHz and then repeats the sweep starting again at 18 kHz. The range of ultrasonic frequencies may be between about 1 kHz and 10 MHz. In some embodiments, the range of ultrasonic frequencies is between about 10 kHz and 50 kHz. In one embodiment, the applied ultrasonic frequency on the ultrasound device 120 is increased and/or decreased in discrete incremental steps though a given frequency range. For example, the applied frequency can start at 18 kHz and increase in 0.1 kHz increments until 22 kHz is reached and then decrease in 0.1 kHz increments until 18 kHz is reached. The sweep interval, or the period of time it takes to sweep through a given frequency range, can also be adjusted and optimized.


The materials for the ultrasound device 120 may be selected to facilitate the penetration and/or ablation by the ultrasound device 120. These different materials can have different physical properties such as hardness or density. Different frequencies of vibration may be preferred over others depending on the physical properties of such materials. In some embodiments, the device is optimized and/or adjusted to penetrate hard plaques and/or rigid deposits and in other embodiments, the device is optimized and/or adjusted to penetrate soft tissues. In some embodiments, the device is optimized and/or adjusted to penetrate fibrous tissue. As such, configuring the system 100 to sweep through a range of frequencies can also increase the likelihood that the ultrasound device 120 will vibrate at the particular frequency and/or wave form best suited for removing the particular material.


In some embodiments, the signal generator 127, ultrasound transducer 126, and/or any other suitable component can be configured to determine the resonant frequency of a particular ultrasound device 120 during use. Once the resonant frequency is determined, the system can then be configured to operate at resonance during use. As discussed above, the resonant frequency for the ultrasound device 120 can change during use due to factors such as, for example, the amount of tortuosity the ultrasound device 120 is subjected to, the temperature, and the load on the distal end 300. The resonant frequency of the system may also change when the transducer changes temperature. In one embodiment, the resonant frequency during use of the device is determined by configuring the signal generator 127, ultrasound transducer 126, and/or any other suitable component to be paused briefly during use. In other words, the ultrasound transducer 126 can momentarily stop transmitting vibrations through the ultrasound device 120. Such stoppages may be intermittent and/or periodic.


While the transmission of vibrations is momentarily stopped, the ultrasound transducer 126 and/or other suitable component can send a measurement pulse through the ultrasound device 120. The measurement pulse can then be used to determine the actual resonance of the ultrasound device 120. The signal generator 127, ultrasound transducer 126, and/or any other suitable component can then be adjusted to deliver this resonant frequency through the ultrasound device 120. In some embodiments, this measurement and adjustment is done automatically. At a later point in time, the transmission of vibrations can again be momentarily stopped, a measurement signal can be sent through the device, the resonant frequency can be determined, and the system can be adjusted to deliver this resonant frequency. As such, in some embodiments, the resonant frequency of the ultrasound device 120 can be determined and the device adjusted to operate at or near resonance during a procedure.


In some embodiments, the ultrasound system 100 is configured such that the displacement of the distal end 300 of the ultrasound device 120 is measured and controlled during use. For example, as shown in FIG. 3, when an ultrasonic wave is transmitted from the ultrasound transducer through the ultrasound transmission member 230 (input wave 505), a portion of the transmitted wave is reflected (reflected wave 510) and a portion of the wave reaches the distal head 500 (transmitted wave 520). Waves can be reflected, as illustrated for example in FIG. 3, at bends in the ultrasound transmission member 230.


The ultrasound transducer 126 or another transducer or device can be configured to detect and measure the amplitude of the reflected wave 510. The difference in amplitude between the input wave 505 and the reflected wave 510 can be used at least in part to determine the amplitude of the transmitted wave 520. As such, the ultrasound system 100 can determine the amplitude of the transmitted wave 520 by comparing the values of the amplitude of the transmitted wave 520 and the amplitude of the reflected wave 510. The device can adjust the amplitude of the input wave based at least in part on amplitude of the transmitted wave 520. For example, the input wave can be adjusted so as to keep the amplitude of the transmitted wave 520 relatively constant. In other words, the displacement of the distal end of the ultrasonic device can be monitored in real time and the ultrasonic drive system can be continually adjusted so that the displacement of the distal tip can be controlled.


The following illustrates an exemplary method of using the ultrasonic system 100 described above. The discussion of this implementation and the example methods of use are meant to augment the description of the invention above and both should be read together. A method of penetrating and/or removing a blockage in the vasculature can begin with positioning an ultrasonic device 120 having a distal end within a blood vessel. The ultrasonic device 120 can include an ultrasonic transmission member surrounded by a catheter body.


The method continues by advancing the ultrasonic device 120 until the distal end is adjacent to a blockage. The ultrasonic device 120 can be advanced using a monorail or over-the-wire technique, with or without the use of a separate guidewire. In some embodiments, the ultrasonic device 120 is positioned so as to abut the blockage. The blockage may be located in a coronary artery. The ultrasonic device 120 can be visualized or otherwise located using a suitable technique known in the art. For example, the ultrasonic device 120 can include one or more radiopaque markers. The method can continue by transmitting a vibration of greater than or equal to about 18 kHz to the distal end of the ultrasound device 120. In some embodiments, the transmitted vibration is greater than about 40 kHz.


In some embodiments, the vibration that is transmitted through the ultrasound device 120 is pulsed and has a duty cycle. The duty cycle and/or frequency of the duty cycle can be optimized for a particular device and/or particular substrate that the device is likely to encounter. In contrast to the application of a continuously applied constant vibration, the application of a pulsed ultrasonic vibration can cause greater displacement and/or more erratic movement of the distal portion of the ultrasonic device which can increase the device's ability to penetrate hard substances.


In some embodiments, the vibration that is transmitted through the ultrasound device 120 starts at a first frequency and changes to at least a second frequency different than the first frequency. In some embodiments, the applied frequency vibration sweeps through a range of frequencies from a first frequency to a second frequency. The sweep can be a continuous sweep though predetermined ranges of frequencies. In some embodiments, the sweep through a range of frequencies comprises discrete incremental steps up and or down through a range of frequencies. In some embodiments the range of ultrasonic frequencies applied to the device is random and/or discontinuous. In some embodiments the range of frequencies includes at least one resonant frequency of the ultrasonic device.


In some embodiments, the resonant frequency of the device is determined and the system drives the ultrasonic device at or near the resonant frequency of the device. The resonant frequency can be determined prior to or during use of the device. In some embodiments the energy that is transmitted through the device can be paused and a measurement signal can be sent through the device. The measurement signal can be used to determine the actual resonant frequency of the device at that particular point in time. The system can then adjust to drive the device at the actual resonant frequency.


In some embodiments, the system determines the displacement of the distal end of the device. The reflected vibrations can be monitored to help determine the amount of ultrasonic energy that reaches the distal end of the device. The applied vibration can then be adjusted based at least in part on how much energy is reflected. That is to say, if the system determines that a large portion of the applied vibration is being reflected, the system can increase the amplitude of the input wave applied to the device. In this way, the drive can be continuously adjusted to help ensure that enough energy is reaching the distal end of the device. In some embodiments, the displacement of the distal tip is kept relatively constant by adjusting the applied wave form based at least in part on the amount of energy that is reflected.


The method can continue by advancing the distal end 300 of the ultrasound device 120 through the blockage. The ultrasound device 120 can then be removed from the patient. In some embodiments, a stent is placed in the vessel.



FIG. 6 is a flow diagram illustrating a method 600 of recanalizing a vessel. The method can begin at block 601 by positioning an ultrasonic device having a distal end in a first position within the lumen of the vessel. The vessel may include a partial or total occlusion. The method 600 can continue at block 603 by transmitting ultrasonic vibrations to the distal end of the ultrasonic device. At least one reflected vibration may be detected at block 605. The method can continue at block 609 by modifying the applied vibration(s) at least in part on the detected vibration(s). The detected vibration(s) may be used to determine a resonant frequency of the ultrasonic device. The applied vibration may then be adjusted. In some embodiments, the adjustment comprises applying the resonant frequency that was determined at least in part by the reflected vibration(s). The method can end by advancing the distal end through the vessel to recanalize the vessel.


The various embodiments described above thus provide a number of ways to provide for treatment of occluded vessels. In addition, the techniques described may be broadly applied for use with a variety of medical procedures. Of course, it is to be understood that not necessarily all such objectives or advantages may be achieved in accordance with any particular embodiment using the systems described herein. Thus, for example, those skilled in the art will recognize that the systems may be developed in a manner that achieves or optimizes one advantage or group of advantages as taught herein without necessarily achieving other objectives or advantages as may be taught or suggested herein.


Furthermore, the skilled artisan will recognize the interchangeability of various features from different embodiments. Although these techniques and devices have been disclosed in the context of certain embodiments and examples, it will be understood by those skilled in the art that these techniques and devices may be extended beyond the specifically disclosed embodiments to other embodiments and/or uses and obvious modifications and equivalents thereof. Additionally, it is contemplated that various aspects and features of the invention described can be practiced separately, combined together, or substituted for one another, and that a variety of combination and subcombinations of the features and aspects can be made and still fall within the scope of the invention. Thus, it is intended that the scope of the systems disclosed herein should not be limited by the particular disclosed embodiments described above.

Claims
  • 1. A method of recanalizing a lumen of a vessel, comprising: positioning an ultrasonic device having a distal end in a first position within the lumen of the vessel;transmitting pulsed ultrasonic vibrations though the ultrasonic device to the distal end; andadvancing the distal end through the lumen to recanalize the vessel;detecting a reflected vibration; anddetecting a displacement of the distal end of the ultrasonic device based on the reflected vibration.
  • 2. The method of claim 1, wherein the pulsed ultrasonic vibrations increase the displacement of the distal end of the ultrasonic device.
  • 3. The method of claim 1, wherein the act of transmitting pulsed ultrasonic vibrations comprises transmitting a first frequency for a first time period and transmitting a second frequency for a second time period.
  • 4. The method of claim 3, wherein the first frequency is at least 18 kHz and the second frequency is about 0 kHz.
  • 5. The method of claim 3 wherein the first and second time periods are between about 5 milliseconds and 30 milliseconds.
  • 6. A method of operating a therapeutic ultrasonic vibration delivery system, comprising: providing an elongate ultrasound transmission device having a distal end and a proximal end;driving the proximal end of the elongate ultrasound transmission device in a pulsed mode, wherein the pulsed mode transmits pulsed ultrasonic vibrations though the elongate ultrasound transmission device to the distal end;detecting a reflected vibration; anddetecting a displacement of the distal end of the elongate ultrasound transmission device based on the reflected vibration.
  • 7. The method of claim 6, wherein the pulsed ultrasonic vibrations displace the distal end of the elongate ultrasound transmission device.
  • 8. The method of claim 7, comprising modifying the pulsed ultrasonic vibrations based at least in part on the detected reflected vibration.
  • 9. The method of claim 6, comprising: positioning the distal end of the elongate ultrasound transmission device in a first position within the lumen of a vessel; andadvancing the distal end of the elongate ultrasound transmission device through the lumen to recanalize the vessel.
  • 10. The method of claim 6, wherein the pulsed mode has a duty cycle of about 50%.
  • 11. The method of claim 6, wherein the pulsed mode has a duty cycle of 60-70%.
  • 12. The method of claim 6, wherein the pulsed mode has a duty cycle of 30-40%.
  • 13. The method of claim 6, comprising selecting a duty cycle of the pulsed mode based on a particular occlusion substrate to be engaged by the distal end of the elongate ultrasound transmission device.
  • 14. The method of claim 6, wherein the pulsed mode comprises applying at least a first frequency for a first time period and a second frequency for a second time period, wherein the first frequency is at least 18 kHz.
  • 15. The method of claim 14, wherein the second frequency is about 0 kHz.
  • 16. The method of claim 14, wherein each of the first time period and the second time period is between 5 milliseconds and 30 milliseconds in duration.
PRIORITY

This application is a division of U.S. patent application Ser. No. 14/415,126, filed Jan. 15, 2015, which is a U.S. national stage application under 35 USC § 371 of International Application No. PCT/US2013/053306, filed Aug. 1, 2013, claiming priority to U.S. Provisional Application No. 61/678,920, filed Aug. 2, 2012, each of which is incorporated by reference in its entirety into this application.

US Referenced Citations (520)
Number Name Date Kind
3296620 Rodda Jan 1967 A
3433226 Boyd Mar 1969 A
3443226 Knight May 1969 A
3565062 Kurls Feb 1971 A
3585082 Siller Jun 1971 A
3612038 Halligan Oct 1971 A
3631848 Muller Jan 1972 A
3679378 Van Impe et al. Jul 1972 A
3719737 Vaillancourt et al. Mar 1973 A
3739460 Addis et al. Jun 1973 A
3754746 Thiele Aug 1973 A
3823717 Pohlman et al. Jul 1974 A
3835690 Leonhardt et al. Sep 1974 A
3839841 Amplatz Oct 1974 A
3896811 Storz Jul 1975 A
4016882 Broadwin et al. Apr 1977 A
4033331 Guss et al. Jul 1977 A
4136700 Broadwin et al. Jan 1979 A
4337090 Harrison Jun 1982 A
4368410 Hance et al. Jan 1983 A
4417578 Banko Nov 1983 A
4425115 Wuchinich Jan 1984 A
4453935 Newton Jun 1984 A
4486680 Bonnet et al. Dec 1984 A
4495232 Bauser et al. Jan 1985 A
4505767 Quin Mar 1985 A
4535759 Polk et al. Aug 1985 A
4545767 Suzuki et al. Oct 1985 A
4565589 Harrison Jan 1986 A
4565787 Bossle et al. Jan 1986 A
4572184 Stohl et al. Feb 1986 A
4664112 Kensey et al. May 1987 A
4665906 Jervis May 1987 A
4679558 Kensey et al. Jul 1987 A
4700705 Kensey et al. Oct 1987 A
4721117 Mar et al. Jan 1988 A
4750902 Wuchinich et al. Jun 1988 A
4781186 Simpson et al. Nov 1988 A
4808153 Parisi Feb 1989 A
4811743 Stevens Mar 1989 A
4827911 Broadwin et al. May 1989 A
4838853 Parisi Jun 1989 A
4854325 Stevens Aug 1989 A
4870953 DonMicheal et al. Oct 1989 A
4886060 Wiksell Dec 1989 A
4920954 Alliger et al. May 1990 A
4923462 Stevens May 1990 A
4924863 Sterzer May 1990 A
4931047 Broadwin et al. Jun 1990 A
4936281 Stasz Jun 1990 A
4936845 Stevens Jun 1990 A
4979952 Kubota et al. Dec 1990 A
5000185 Yock Mar 1991 A
5015227 Broadwin et al. May 1991 A
5026384 Farr et al. Jun 1991 A
5030201 Palestrant Jul 1991 A
5030357 Lowe Jul 1991 A
5046503 Schneiderman Sep 1991 A
5053008 Bajaj Oct 1991 A
5058570 Idemoto et al. Oct 1991 A
5076276 Sakurai et al. Dec 1991 A
5091205 Fan Feb 1992 A
5100423 Fearnot Mar 1992 A
5109859 Jenkins May 1992 A
5114414 Buchbinder May 1992 A
5116350 Stevens May 1992 A
5127917 Niederhauser et al. Jul 1992 A
5131393 Ishiguro et al. Jul 1992 A
5156143 Bocquet et al. Oct 1992 A
5163421 Bernstein et al. Nov 1992 A
5171216 Dasse et al. Dec 1992 A
5180363 Idemoto et al. Jan 1993 A
5183470 Wettermann Feb 1993 A
5195955 Don Michael Mar 1993 A
5215614 Wijkamp et al. Jun 1993 A
5217565 Kou et al. Jun 1993 A
5221255 Mahurkar et al. Jun 1993 A
5226421 Frisbie et al. Jul 1993 A
5234416 Macaulay et al. Aug 1993 A
5236414 Takasu Aug 1993 A
5238004 Sahatjian et al. Aug 1993 A
5242385 Strukel Sep 1993 A
5243997 Uflacker et al. Sep 1993 A
5248296 Alliger Sep 1993 A
5255669 Kubota et al. Oct 1993 A
5267954 Nita Dec 1993 A
5269291 Carter Dec 1993 A
5269297 Weng et al. Dec 1993 A
5269793 Simpson Dec 1993 A
5279546 Mische et al. Jan 1994 A
5287858 Hammerslag et al. Feb 1994 A
5290229 Paskar Mar 1994 A
5304115 Pflueger et al. Apr 1994 A
5304131 Paskar Apr 1994 A
5312328 Nita et al. May 1994 A
5318014 Carter Jun 1994 A
5318570 Hood et al. Jun 1994 A
5324255 Passafaro et al. Jun 1994 A
5324260 O'Neill et al. Jun 1994 A
5325860 Seward et al. Jul 1994 A
5326342 Pflueger et al. Jul 1994 A
5328004 Fannin et al. Jul 1994 A
5329927 Gardineer et al. Jul 1994 A
5341818 Abrams et al. Aug 1994 A
5342292 Nita et al. Aug 1994 A
5344395 Whalen et al. Sep 1994 A
5346502 Estabrook et al. Sep 1994 A
5362309 Carter Nov 1994 A
5368557 Nita Nov 1994 A
5368558 Nita et al. Nov 1994 A
5376084 Bacich et al. Dec 1994 A
5378234 Hammerslag et al. Jan 1995 A
5380274 Nita Jan 1995 A
5380316 Aita et al. Jan 1995 A
5382228 Nita et al. Jan 1995 A
5383460 Jang et al. Jan 1995 A
5389096 Aita et al. Feb 1995 A
5391144 Sakurai et al. Feb 1995 A
5397293 Alliger et al. Mar 1995 A
5397301 Pflueger et al. Mar 1995 A
5403324 Ciervo et al. Apr 1995 A
5405318 Nita Apr 1995 A
5409483 Campbell et al. Apr 1995 A
5417672 Nita et al. May 1995 A
5417703 Brown et al. May 1995 A
5421923 Clarke et al. Jun 1995 A
5427118 Nita et al. Jun 1995 A
5431168 Webster, Jr. Jul 1995 A
5431663 Carter Jul 1995 A
5443078 Uflacker Aug 1995 A
5447509 Mills et al. Sep 1995 A
5449369 Imran Sep 1995 A
5449370 Vaitekunas Sep 1995 A
5451209 Ainsworth et al. Sep 1995 A
5452611 Jones Sep 1995 A
5462529 Simpson et al. Oct 1995 A
5465733 Hinohara et al. Nov 1995 A
5474530 Passafaro et al. Dec 1995 A
5474531 Carter Dec 1995 A
5480379 La Rosa Jan 1996 A
5484398 Stoddard Jan 1996 A
5487757 Truckai et al. Jan 1996 A
5498236 Dubrul et al. Mar 1996 A
5507738 Ciervo Apr 1996 A
5516043 Manna et al. May 1996 A
5527273 Manna et al. Jun 1996 A
5538512 Zenzon et al. Jul 1996 A
5540656 Pflueger et al. Jul 1996 A
5542917 Nita et al. Aug 1996 A
5597497 Dean et al. Jan 1997 A
5597882 Schiller et al. Jan 1997 A
5607421 Jeevanandam et al. Mar 1997 A
5611807 O'Boyle Mar 1997 A
5618266 Liprie Apr 1997 A
5626593 Imran May 1997 A
5627365 Chiba et al. May 1997 A
5649935 Kremer et al. Jul 1997 A
5658282 Daw et al. Aug 1997 A
5665062 Houser Sep 1997 A
5685841 Mackool Nov 1997 A
5695460 Siegel et al. Dec 1997 A
5695507 Auth et al. Dec 1997 A
5715825 Crowley Feb 1998 A
5720724 Ressemann et al. Feb 1998 A
5725494 Brisken Mar 1998 A
5728062 Brisken Mar 1998 A
5738100 Kagami et al. Apr 1998 A
5797876 Spears et al. Aug 1998 A
5816923 Milo et al. Oct 1998 A
5827203 Nita Oct 1998 A
5827971 Hale et al. Oct 1998 A
5830127 DeCastro Nov 1998 A
5830222 Makower Nov 1998 A
5846218 Brisken et al. Dec 1998 A
5873835 Hastings et al. Feb 1999 A
5876385 Ikari et al. Mar 1999 A
5893838 Daoud et al. Apr 1999 A
5895397 Jang et al. Apr 1999 A
5902287 Martin May 1999 A
5904667 Falwell May 1999 A
5916192 Nita et al. Jun 1999 A
5916912 Ames et al. Jun 1999 A
5935142 Hood Aug 1999 A
5935144 Estabrook Aug 1999 A
5937301 Gardner et al. Aug 1999 A
5944737 Tsonton et al. Aug 1999 A
5957882 Nita et al. Sep 1999 A
5957899 Spears et al. Sep 1999 A
5964223 Baran Oct 1999 A
5967984 Chu et al. Oct 1999 A
5971949 Levin et al. Oct 1999 A
5976119 Spears et al. Nov 1999 A
5989208 Nita Nov 1999 A
5989275 Estabrook et al. Nov 1999 A
5997497 Nita et al. Dec 1999 A
6004280 Buck et al. Dec 1999 A
6004335 Vaitekunas et al. Dec 1999 A
6007499 Martin et al. Dec 1999 A
6007514 Nita Dec 1999 A
6022309 Celliers et al. Feb 2000 A
6024764 Schroeppel Feb 2000 A
6029671 Stevens et al. Feb 2000 A
6030357 Daoud et al. Feb 2000 A
6036689 Tu et al. Mar 2000 A
6051010 DiMatteo et al. Apr 2000 A
6066135 Honda May 2000 A
6113558 Rosenschein et al. Sep 2000 A
6120515 Rogers et al. Sep 2000 A
6123698 Spears et al. Sep 2000 A
6142971 Daoud et al. Nov 2000 A
6149596 Bancroft Nov 2000 A
6159176 Broadwin et al. Dec 2000 A
6159187 Park et al. Dec 2000 A
6165127 Crowley Dec 2000 A
6165188 Saadat et al. Dec 2000 A
6179809 Khairkhahan et al. Jan 2001 B1
6180059 Divino, Jr. et al. Jan 2001 B1
6190353 Makower et al. Feb 2001 B1
6206842 Tu et al. Mar 2001 B1
6210356 Anderson et al. Apr 2001 B1
6217543 Anis et al. Apr 2001 B1
6217565 Cohen Apr 2001 B1
6217588 Jerger et al. Apr 2001 B1
6221015 Vock Apr 2001 B1
6231546 Milo et al. May 2001 B1
6231587 Makower May 2001 B1
6235007 Divino, Jr. et al. May 2001 B1
6241692 Tu et al. Jun 2001 B1
6241703 Levin et al. Jun 2001 B1
6241744 Imran et al. Jun 2001 B1
6248087 Spears et al. Jun 2001 B1
6277084 Abele et al. Aug 2001 B1
6283983 Makower et al. Sep 2001 B1
6287271 Dubrul et al. Sep 2001 B1
6287285 Michal et al. Sep 2001 B1
6287317 Makower et al. Sep 2001 B1
6296620 Gesswein et al. Oct 2001 B1
6298620 Hatzinikolas Oct 2001 B1
6302875 Makower et al. Oct 2001 B1
6309358 Okubo Oct 2001 B1
6315741 Martin et al. Nov 2001 B1
6315754 Daoud et al. Nov 2001 B1
6331171 Cohen Dec 2001 B1
6346192 Buhr et al. Feb 2002 B2
6379378 Werneth et al. Apr 2002 B1
6387109 Davison et al. May 2002 B1
6387324 Patterson et al. May 2002 B1
6394956 Chandrasekaran et al. May 2002 B1
6398736 Seward Jun 2002 B1
6409673 Yock Jun 2002 B2
6416533 Gobin et al. Jul 2002 B1
6423026 Gesswein et al. Jul 2002 B1
6427118 Suzuki Jul 2002 B1
6433464 Jones Aug 2002 B2
6434418 Neal et al. Aug 2002 B1
6450975 Brennan et al. Sep 2002 B1
6454737 Nita et al. Sep 2002 B1
6454757 Nita et al. Sep 2002 B1
6454997 Divino, Jr. et al. Sep 2002 B1
6484052 Visuri et al. Nov 2002 B1
6491707 Makower et al. Dec 2002 B2
6494891 Cornish et al. Dec 2002 B1
6494894 Mirarchi Dec 2002 B2
6500141 Irion et al. Dec 2002 B1
6508781 Brennan et al. Jan 2003 B1
6508784 Shu Jan 2003 B1
6511458 Milo et al. Jan 2003 B2
6514249 Maguire et al. Feb 2003 B1
6524251 Rabiner et al. Feb 2003 B2
6533766 Patterson et al. Mar 2003 B1
6544215 Bencini et al. Apr 2003 B1
6547754 Evans et al. Apr 2003 B1
6547788 Maguire Apr 2003 B1
6551337 Rabiner et al. Apr 2003 B1
6554846 Hamilton et al. Apr 2003 B2
6555059 Myrick et al. Apr 2003 B1
6558502 Divino, Jr. et al. May 2003 B2
6562031 Chandrasekaran et al. May 2003 B2
6573470 Brown et al. Jun 2003 B1
6576807 Brunelot et al. Jun 2003 B1
6582387 Derek et al. Jun 2003 B2
6589253 Cornish et al. Jul 2003 B1
6595989 Schaer Jul 2003 B1
6596235 Divino, Jr. et al. Jul 2003 B2
6602467 Divino, Jr. et al. Aug 2003 B1
6602468 Patterson et al. Aug 2003 B2
6605217 Buhr et al. Aug 2003 B2
6607698 Spears et al. Aug 2003 B1
6610077 Hancock et al. Aug 2003 B1
6613280 Myrick et al. Sep 2003 B2
6615062 Ryan et al. Sep 2003 B2
6616617 Ferrera et al. Sep 2003 B1
6622542 Derek et al. Sep 2003 B2
6623448 Slater Sep 2003 B2
6635017 Moehring et al. Oct 2003 B1
6650923 Lesh et al. Nov 2003 B1
6652547 Rabiner et al. Nov 2003 B2
6660013 Rabiner et al. Dec 2003 B2
6676900 Divino, Jr. et al. Jan 2004 B1
6682502 Bond et al. Jan 2004 B2
6685657 Jones Feb 2004 B2
6689086 Nita et al. Feb 2004 B1
6695781 Rabiner et al. Feb 2004 B2
6695782 Ranucci et al. Feb 2004 B2
6695810 Peacock, III et al. Feb 2004 B2
6702748 Nita et al. Mar 2004 B1
6702750 Yock Mar 2004 B2
6719715 Newman et al. Apr 2004 B2
6719725 Milo et al. Apr 2004 B2
6729334 Baran May 2004 B1
6733451 Rabiner et al. May 2004 B2
6758846 Goble et al. Jul 2004 B2
6761698 Shibata et al. Jul 2004 B2
6814727 Mansouri-Ruiz Nov 2004 B2
6855123 Nita Feb 2005 B2
6866670 Rabiner et al. Mar 2005 B2
6936025 Evans et al. Aug 2005 B1
6936056 Nash et al. Aug 2005 B2
6942620 Nita et al. Sep 2005 B2
6942677 Nita et al. Sep 2005 B2
6955680 Satou et al. Oct 2005 B2
7004173 Sparks et al. Feb 2006 B2
7004176 Lau Feb 2006 B2
7056294 Khairkhahan et al. Jun 2006 B2
7131983 Murakami Nov 2006 B2
7137963 Nita et al. Nov 2006 B2
7149587 Wardle et al. Dec 2006 B2
7150853 Lee et al. Dec 2006 B2
7166098 Steward et al. Jan 2007 B1
7220233 Nita et al. May 2007 B2
7267650 Chow et al. Sep 2007 B2
7297131 Nita Nov 2007 B2
7335180 Nita et al. Feb 2008 B2
7341569 Soltani et al. Mar 2008 B2
7384407 Rodriguez et al. Jun 2008 B2
7393338 Nita Jul 2008 B2
7421900 Karasawa et al. Sep 2008 B2
7425198 Moehring et al. Sep 2008 B2
7494468 Rabiner et al. Feb 2009 B2
7503895 Rabiner et al. Mar 2009 B2
7540852 Nita et al. Jun 2009 B2
7604608 Nita et al. Oct 2009 B2
7621902 Nita et al. Nov 2009 B2
7621929 Nita et al. Nov 2009 B2
7628763 Noriega et al. Dec 2009 B2
7648478 Soltani et al. Jan 2010 B2
7758510 Nita et al. Jul 2010 B2
7771358 Moehring et al. Aug 2010 B2
7771452 Pal et al. Aug 2010 B2
7775994 Lockhart Aug 2010 B2
7776025 Bobo, Jr. Aug 2010 B2
7819013 Chan et al. Oct 2010 B2
7850623 Griffin et al. Dec 2010 B2
7918819 Karmarkar et al. Apr 2011 B2
7935108 Baxter et al. May 2011 B2
7938819 Kugler et al. May 2011 B2
7942809 Leban May 2011 B2
7955293 Nita et al. Jun 2011 B2
7993308 Rule et al. Aug 2011 B2
8038693 Allen Oct 2011 B2
8043251 Nita et al. Oct 2011 B2
8052607 Byrd Nov 2011 B2
8083727 Kugler et al. Dec 2011 B2
8133236 Nita Mar 2012 B2
8152753 Nita et al. Apr 2012 B2
8172758 Harhen May 2012 B2
8221343 Nita et al. Jul 2012 B2
8226566 Nita Jul 2012 B2
8246643 Nita Aug 2012 B2
8257378 O'connor Sep 2012 B1
8308677 Nita et al. Nov 2012 B2
8343134 Kost et al. Jan 2013 B2
8414543 Mcguckin, Jr. et al. Apr 2013 B2
8496669 Nita et al. Jul 2013 B2
8506519 Nita Aug 2013 B2
8613700 Ueno et al. Dec 2013 B2
8613751 Nita et al. Dec 2013 B2
8617096 Nita et al. Dec 2013 B2
8632560 Pal et al. Jan 2014 B2
8641630 Nita et al. Feb 2014 B2
8647293 Nita Feb 2014 B2
8647296 Moberg et al. Feb 2014 B2
8663259 Levine et al. Mar 2014 B2
8668709 Nita et al. Mar 2014 B2
8690818 Bennett et al. Apr 2014 B2
8690819 Nita et al. Apr 2014 B2
8702595 Ueki Apr 2014 B2
8708892 Sugiyama et al. Apr 2014 B2
8708994 Pettis et al. Apr 2014 B2
8725228 Koblish et al. May 2014 B2
8764700 Zhang et al. Jul 2014 B2
8768433 Jenkins et al. Jul 2014 B2
8790291 Nita et al. Jul 2014 B2
8974446 Nguyen et al. Mar 2015 B2
8978478 Ishioka Mar 2015 B2
9101387 Plowe et al. Aug 2015 B2
9107590 Hansmann et al. Aug 2015 B2
9237837 Omoto et al. Jan 2016 B2
9265520 Nita Feb 2016 B2
9282984 Nita Mar 2016 B2
9314258 Nita et al. Apr 2016 B2
9381027 Nita et al. Jul 2016 B2
9421024 Nita et al. Aug 2016 B2
9433433 Nita et al. Sep 2016 B2
9603615 Sarge Mar 2017 B2
9770250 Nita et al. Sep 2017 B2
9955994 Nita May 2018 B2
10004520 Nita et al. Jun 2018 B2
20020022858 Demond et al. Feb 2002 A1
20020049409 Noda et al. Apr 2002 A1
20020077550 Rabiner et al. Jun 2002 A1
20020188276 Evans et al. Dec 2002 A1
20020189357 Lai et al. Dec 2002 A1
20030009153 Brisken et al. Jan 2003 A1
20030036705 Hare et al. Feb 2003 A1
20030040762 Dorros et al. Feb 2003 A1
20030060820 Maguire Mar 2003 A1
20030199817 Thompson et al. Oct 2003 A1
20030216732 Truckai et al. Nov 2003 A1
20030225332 Okada et al. Dec 2003 A1
20040019349 Fuimaono et al. Jan 2004 A1
20040024393 Nita et al. Feb 2004 A1
20040054367 Teodoro, Jr. et al. Mar 2004 A1
20040164030 Lowe et al. Aug 2004 A1
20040167511 Buehlmann et al. Aug 2004 A1
20040193033 Badehi et al. Sep 2004 A1
20050033311 Guldfeldt et al. Feb 2005 A1
20050119606 Nita Jun 2005 A1
20050149110 Wholey et al. Jul 2005 A1
20050165388 Bhola Jul 2005 A1
20050171527 Bhola Aug 2005 A1
20050228286 Messerly et al. Oct 2005 A1
20060074441 Mcguckin, Jr. et al. Apr 2006 A1
20060116610 Hare Jun 2006 A1
20060149169 Nunomura et al. Jul 2006 A1
20060206028 Lee Sep 2006 A1
20060206039 Wilson et al. Sep 2006 A1
20060264809 Hansmann et al. Nov 2006 A1
20070032749 Overall et al. Feb 2007 A1
20070161945 Nita et al. Jul 2007 A1
20070178768 Harshman et al. Aug 2007 A1
20080033284 Hauck Feb 2008 A1
20080071343 Mayberry et al. Mar 2008 A1
20080208084 Horzewski et al. Aug 2008 A1
20080221506 Rodriguez et al. Sep 2008 A1
20080294037 Richter Nov 2008 A1
20090017293 Arai et al. Jan 2009 A1
20090143795 Robertson Jun 2009 A1
20090209900 Carmeli Aug 2009 A1
20090292296 Pansky Nov 2009 A1
20100004558 Frankhouser et al. Jan 2010 A1
20100023037 Nita et al. Jan 2010 A1
20100069854 Okoh et al. Mar 2010 A1
20100076454 Bos Mar 2010 A1
20100121144 Farhadi May 2010 A1
20100217306 Raabe et al. Aug 2010 A1
20100268206 Manwaring et al. Oct 2010 A1
20110046522 Chan et al. Feb 2011 A1
20110105960 Wallace May 2011 A1
20110130834 Wilson et al. Jun 2011 A1
20110196384 Pansky Aug 2011 A1
20110196399 Robertson et al. Aug 2011 A1
20110196403 Robertson et al. Aug 2011 A1
20110237982 Wallace Sep 2011 A1
20110313328 Nita Dec 2011 A1
20120010506 Ullrich Jan 2012 A1
20120109021 Hastings et al. May 2012 A1
20120130475 Shaw May 2012 A1
20120217306 Morrill Webb et al. Aug 2012 A1
20120238916 Nita et al. Sep 2012 A1
20120238946 Nita et al. Sep 2012 A1
20120311844 Nita et al. Dec 2012 A1
20120330196 Nita Dec 2012 A1
20130046297 Lingeman et al. Feb 2013 A1
20130060169 Kamada Mar 2013 A1
20130066200 Frankhouser Mar 2013 A1
20130331652 Okamoto Dec 2013 A1
20130338580 Kamatani et al. Dec 2013 A1
20140005706 Gelfand et al. Jan 2014 A1
20140012087 Omoto Jan 2014 A1
20140039491 Bakos et al. Feb 2014 A1
20140171804 Van Hoven Jun 2014 A1
20140236118 Unser et al. Aug 2014 A1
20140243712 Humayun et al. Aug 2014 A1
20140350401 Sinelnikov Nov 2014 A1
20140358028 Vetter et al. Dec 2014 A1
20140358029 Vetter et al. Dec 2014 A1
20150025544 Nita et al. Jan 2015 A1
20150073357 Bagwell et al. Mar 2015 A1
20150105621 Farhadi Apr 2015 A1
20150105715 Pikus et al. Apr 2015 A1
20150133918 Sachar May 2015 A1
20150148795 Amos et al. May 2015 A1
20150157443 Hauser et al. Jun 2015 A1
20150190660 Sarge et al. Jul 2015 A1
20150297258 Escudero et al. Oct 2015 A1
20150359651 Wübbeling Dec 2015 A1
20160128717 Nita May 2016 A1
20160128767 Azamian et al. May 2016 A1
20160135835 Onuma May 2016 A1
20160183956 Nita Jun 2016 A1
20160183963 Richter Jun 2016 A1
20160271362 Van Liere Sep 2016 A1
20160328998 Nita et al. Nov 2016 A1
20160338722 Nita et al. Nov 2016 A1
20160367284 Nita et al. Dec 2016 A1
20170065288 Imai et al. Mar 2017 A1
20170128090 Sarge May 2017 A1
20170224375 Robertson et al. Aug 2017 A1
20170265879 Washburn, II et al. Sep 2017 A1
20170265886 Nita et al. Sep 2017 A1
20170354428 Nita et al. Dec 2017 A1
20180042636 Nita Feb 2018 A1
20180140321 Deepa May 2018 A1
20180168668 Zheng Jun 2018 A1
20180177515 Boyle et al. Jun 2018 A1
20180197856 Chou et al. Jul 2018 A1
20180221040 Roll Hoye Aug 2018 A1
20180280005 Parmentier Oct 2018 A1
20180280044 Nita et al. Oct 2018 A1
Foreign Referenced Citations (73)
Number Date Country
2007240154 Jan 2008 AU
2256127 May 1974 DE
2438648 Feb 1976 DE
8910040 Dec 1989 DE
3821836 Jan 1990 DE
4042435 Feb 1994 DE
10146011 Apr 2003 DE
0005719 Dec 1979 EP
0316789 May 1989 EP
0316796 May 1989 EP
0376562 Jul 1990 EP
0379156 Jul 1990 EP
0394583 Oct 1990 EP
0443256 Aug 1991 EP
0472368 Feb 1992 EP
0541249 May 1993 EP
0820728 Jan 1998 EP
1323481 Jul 2003 EP
1106957 Mar 1968 GB
H2-7150 Oct 1988 JP
01-099547 Apr 1989 JP
6086822 Mar 1994 JP
H07500752 Jan 1995 JP
7116260 May 1995 JP
9-503137 Mar 1997 JP
10-216140 Aug 1998 JP
2000-291543 Oct 2000 JP
2001-104356 Apr 2001 JP
2001-321388 Nov 2001 JP
2002-186627 Jul 2002 JP
2005-253874 Sep 2005 JP
2006-522644 Oct 2006 JP
2007512087 May 2007 JP
2007520255 Jul 2007 JP
8705739 Sep 1987 WO
8705793 Oct 1987 WO
8906515 Jul 1989 WO
8001300 Feb 1990 WO
8004362 May 1990 WO
9107917 Jun 1991 WO
9211815 Jul 1992 WO
9308750 May 1993 WO
9316646 Sep 1993 WO
9412140 Jun 1994 WO
9414382 Jul 1994 WO
9508954 Apr 1995 WO
9509571 Apr 1995 WO
9515192 Jun 1995 WO
9635469 Nov 1996 WO
9705739 Feb 1997 WO
9721462 Jun 1997 WO
9745078 Dec 1997 WO
9827874 Jul 1998 WO
9835721 Aug 1998 WO
9851224 Nov 1998 WO
9852637 Nov 1998 WO
9925412 May 1999 WO
0053341 Sep 2000 WO
0067830 Nov 2000 WO
02094103 Nov 2002 WO
03039381 May 2003 WO
2004012609 Feb 2004 WO
2004093736 Nov 2004 WO
2004112888 Dec 2004 WO
2005053769 Jun 2005 WO
2005112770 Dec 2005 WO
2006049593 May 2006 WO
2013109269 Jul 2013 WO
2014022716 Feb 2014 WO
2014105754 Jul 2014 WO
2014106847 Jul 2014 WO
2018097856 May 2018 WO
20180187159 Oct 2018 WO
Non-Patent Literature Citations (29)
Entry
Noone, D.: Experimental and Numerical Investigation of Wire Waveguides for Therapeutic Ultrasound Angioplasty. M.Eng. Dublin City University. 2008.
Definition of the term “connected”, retrieved on Sep. 21, 2013. <www.thefreedictionary.com/connected> 1 page total.
Supplemental European Search Report dated Nov. 5, 2009 for European Application No. EP03766931.
International Search Report dated Oct. 28, 2003 for PCT Application No. PCT/US2003/023468.
Extended European Search Report dated Mar. 22, 2012 for European Application No. EP11188799.
International Search Report dated Dec. 23, 2005 for PCT Application No. PCT/US2004/019378.
Extended European Search Report for Patent Application No. 06718204.8, dated May 30, 2012.
International Search Report dated Aug. 1, 2013 for PCT Application No. PCT/US2013/053306.
International Preliminary Report dated Aug. 1, 2013 for PCT Application No. PCT/US2013/053306.
Written Opinion dated Aug. 1, 2013 for PCT Application No. PCT/US2013/053306.
Supplemental European Search Report dated Apr. 29, 2009 for European Application No. EP 04711207.3.
Office Action dated Aug. 3, 2010 from Japanese Application No. 2006-517355 filed on Jun. 16, 2004.
Office Action dated Jan. 26, 2010 from Japanese Application No. 2006-517355 filed on Jun. 16, 2004.
International Preliminary Report and Written Opinion dated Aug. 1, 2017 for PCT Application No. PCT/US2017/030675.
International Preliminary Report and Written Opinion dated Feb. 6, 2018 for PCT Application No. PCT/US2018/017022.
Extended European Search Report dated Mar. 5, 2012 for European Application No. 12153606.4-1269.
MargareT Fyfe et al., Mast cell degranulation and increased vascular permeability induced by therapeutic' ultrasound in the rate ankle joint, Br. J. exp. Path., 1984, vol. 65, pp. 671-676.
“Irradiation, Biological, and Other Technologies: E-beam, Biological, and Sharps Treatment Systems”, Non-Incineration Medical Waste Treatment Technologies, Aug. 2001, Chapter 9, pp. 69-74, Health Care Without Harm, Washington, DC.
Paul Yock et al., Catheter-Based Ultrasound Thrombolysis Shake, Rattle, and Reperfuse, https://doi.org/10.1161/01.CIR.95.6.1360 Circulation. 1997;95:1360-1362 Originally published Mar. 18, 1997.
Calhoun et al., “Electron-Beam Systems for Medical Device Sterilization”, downloaded from web on Oct. 8, 2002 <http://www.devicelink.com/mpb/archive/97/07/002.html> 7 pages total.
Definition of the term “coupled”, retrieved on May 18, 2013. <http://www.merriam-webster.com/dictionary/couple> 1 page total.
“E-Beam Theory” RDI-IBA Technology Group, downloaded from web on Oct. 8, 2002 <http://www.e-beamrdi/EbeamTheory.htm> 2 pages total.
Office Action dated May 20, 2010 from Japanese Application No. 2006-541200 filed on Oct. 25, 2004.
Office Action dated Oct. 11, 2012 from Japanese Application No. 2010-181956.
Japanese Office Action for Japanese Application No. 2010-134566, dated Mar. 2, 2012.
Sehgal, et al., Ultrasound-Assisted Thrombolysis, Investigative Radiology, 1993, vol. 28, Issue 10, pp. 939-943.
Siegel, et al., “In Vivo Ultrasound Arterial Recanalization of Atherosclerotic Total Occlusions”, Journal of the American College of Cardiology, Feb. 1990, vol. 15, No. 2, pp. 345-351.
“What is Electron Beam Curing?” downloaded from web on Nov. 14, 2002, 4 pages total. <http://www.ms.oml.gov/researchgroups/composites/new%20orccmt%20pages/pages/ebwha>.
EP Extended Search Report dated Aug. 13, 2009; Application 04710537.5-1269, 5 pages.
Related Publications (1)
Number Date Country
20190151684 A1 May 2019 US
Provisional Applications (1)
Number Date Country
61678920 Aug 2012 US
Divisions (1)
Number Date Country
Parent 14415126 US
Child 16257774 US